b**********e
发帖数: 74 | 1 Echo Therapeutics - Trading Symbol: ECTE OTC股票
First....I want you to pay close attention to what I am seeing in the price
chart pattern.
1) 最近交易量明显上涨， 几天前52w新高
"Stocks that make 52 week highs have a tendency to continue to make new 52
week highs."
2) MACD RSI Accum Trix bullish
3) 技术来说已经超买了， 但是STO 最好用来解释 consolidation的了， or non-
trending markets。 ECTE自12月来一直都是强势， 始终保持overbought， 觉得还会
有momentum
4) 如果ECTE 破 $2.15 resistance (and hold above it), 下个resistance看到 Sept
'08 high of $2.50. 如果 掉下1.75 support level, 大家就洗洗睡吧 觉得 若进入
$2.20-2.30 range. 就会有一个a continued trend.
相关FA 介绍
Echo Therapeutics (ECTE) is a transdermal medical device company developing
its needle-free Symphony tCGM System as a non-invasive, wireless,
transdermal continuous glucose monitoring (tCGM) system and its Prelude
SkinPrep System as a platform technology for transdermal drug delivery.
The Company believes that the Symphony tCGM System will change the paradigm
of invasive, needle-based, episodic glucose testing in the diabetes consumer
and hospital critical care markets to one of continuous, needle-free
monitoring.
So now that you know what this Company does, let me share with you some
reasons why I think this stock has AMAZING GROWTH POTENTIAL.
Echo Therapeutics (ECTE)---has core technologies which include 1) the
Prelude SkinPrep System that incorporates the Company's PATENTED, feedback
permeation control software and 2) Symphony tCGM which provides reliable, on
-demand glucose data continuously (readings obtained every minute),
conveniently and cost-effectively.
Echo Therapeutics (ECTE)--- is positioned to be "first-to-market" with tCGM
in hospitals
Echo Therapeutics (ECTE) --- has had six consecutive positive pilot studies
in glucose monitoring to date.
Echo Therapeutics (ECTE) --- has a pivotal trial and PMA filing for Symphony
anticipated in 2010 for glucose monitoring.
Echo Therapeutics (ECTE) --- projects revenues to begin during the second
quarter with initial critical care and hospital market opportunities greater
than $1 billion.
Echo Therapeutics (ECTE) ---has additional upside potential and partnership
possibilities create MULTI-BILLION DOLLAR OPPORTUNITIES with general
population use.
Now, for MORE positive news...
The company issues a year-end update on December 29th that was full of
positive news for the company:
* ECTE entered into a $15 million license agreement with Ferndale Pharma
Group, Inc. which granted to Ferndale the right to develop, market and sell
Echo's Prelude SkinPrep System for enhanced delivery of Ferndale's topical
lidocaine product, LMX4, in North America and the United Kingdom.
* ECTE also entered into a potentially multi-million dollar license
agreement with Handok Pharmaceuticals Co., Ltd. which granted Handok a
license to develop, market and sell Echo's Symphony tCGM System for needle-
free continuous glucose monitoring in South Korea.
* Echo's medical device patent portfolio consists of 7 U.S. patents and
4 foreign patents, as well as 8 U.S. patent applications and 37 foreign
patent applications.
* In the fourth quarter of 2009, Echo completed private placements of
common stock and warrants to purchase common stock for approximately $4.0
million through the sale of approximately 2.3 million shares of common stock
at $1.25 per share.
* The company is working on several financial initiatives for 2010
including becoming AMEX or NASDAQ listed
最近yahoo news
http://finance.yahoo.com/news/Echo-Therapeutics-Provides-prnews-627914949.html?x=0&.v=1
不知道为啥他家是OTC的, 大家说说吧
不知道有几个人 有耐心看完。 :) |
|
